Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript Summary
Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript Summary
Adjusted EBITDA loss reduced by 50% YoY in Q3.The following is a summary of the Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript:
以下是Standard BioTools Inc.（LAB）2024年第三季度業績會交易摘要：
Financial Performance:
金融業績：
Q3 revenue was $45 million, a 5% decrease YoY; non-GAAP gross margin increased to 57%.
Adjusted EBITDA loss reduced by 50% YoY in Q3.
第三季度營業收入爲4500萬美元，同比下降5％；非通用會計原則毛利率提高至57％。
第三季度調整後的EBITDA虧損同比減少50％。
Business Progress:
業務進展：
Achieved significant integration progress with SomaLogic, expecting $80 million savings in synergies by 2025.
Launched single SOMAmer agents, expanding protein identification services.
與SomaLogic取得重大整合進展，預計到2025年通過協同效應節省8000萬美元。
推出單一SOMAmer代理，拓展蛋白質鑑定服務。
Opportunity:
機會：
Expansion plans with Illumina's platforms could broaden market for SomaScan technology.
Positioned to use strong cash position for future growth and operational scaling.
通過與illumina的平台合作，能夠拓展SomaScan技術的市場。
憑藉雄厚的現金儲備，定位於未來增長和運營規模的利用。
Risk:
風險：
Revenue decline in instrument sales due to capital spending constraints and challenges in China.
Dependence on large contracts introduces revenue volatility.
儀器銷售收入下降，原因是受到資本支出限制和中國市場挑戰的影響。
對大型合同的依賴引入了營業收入的波動性。
Financial Performance:
金融業績：
Q3 revenue totaled $45 million, down 5% year-over-year.
Year-to-date revenue at $128 million, showing a 9% drop compared to previous year.
Q3 non-GAAP gross margin improved to 57%, up from 52% year-over-year.
Non-GAAP operating expenses fell 24% year-over-year in Q3, demonstrating effective cost control.
Adjusted EBITDA showed a substantial reduction in loss by 50% year-over-year in Q3.
第三季度的營業收入總額爲4500萬美元，同比下降5%。
年至今的營業收入爲12800萬美元，與去年同期相比下降了9%。
Q3非GAAP毛利率改善至57%，同比提高了5個百分點，高於去年的52%。
非GAAP營業費用在Q3同比下降24%，展示了有效的成本控制。
調整後的EBITDA在Q3同比減少50%，顯示出虧損顯著降低。
Business Progress:
業務進展：
Significant progress in SomaLogic integration, achieving a full year ahead in cost reduction, totaling $80 million in synergies expected to be fully realized by 2025.
Focus on expanding service offerings, particularly SomaScan, which saw double-digit growth outside top five customers.
Highlighted the rollout of the SomaScan assay on Illumina's installed base projected for the first half of 2025.
Launched single SOMAmer agents as a product, expanding protein identification services.
Targeting adjusted EBITDA break even by the full year 2026 while pursuing long-term profitability.
在SomaLogic整合方面取得重大進展，實現了成本降低提前一年完成，預計到2025年將實現總計8,000萬美元的協同效應。
專注於拓展服務業務，特別是SomaScan，在前五大客戶以外實現了兩位數的增長。
強調計劃在2025年上半年就在illumina的已裝機底下推出SomaScan測定。
推出單一SOMAmer代理作爲產品，拓展蛋白質鑑定服務。
計劃到2026年整體實現調整後的EBITDA達到盈虧平衡，同時追求長期盈利能力。
Opportunities:
機會：
Continues to expand and diversify customer base beyond major SomaScan clients, leading to revenue growth in lab services from new users.
Advanced plans for significant expansion through integration with Illumina's platforms, broadening market reach for the SomaScan technology.
Positioned to leverage strong cash and investment position to drive future growth and operational scaling.
繼續擴大和多樣化客戶群，超越主要SomaScan客戶，從新用戶中實現實驗室服務的營業收入增長。
通過與illumina平台整合，計劃大規模擴展，拓寬SomaScan技術的市場覆蓋範圍。
憑藉強大的現金與投資狀況，有望推動未來增長和業務規模化。
Risks:
風險：
Revenue from instruments dropped significantly, particularly due to external capital spending constraints and market challenges in China, leading to delayed sales and elongated cycles.
Dependence on large contracts can lead to revenue volatility, as seen with the quarter-to-quarter variations influenced by client project timing and execution.
儀器營業收入顯著下降，主要是由於中國市場的外部資本支出限制和市場挑戰導致銷售延遲和週期拉長。
依賴於大型合同可能導致營收波動，正如季度營收波動受到客戶項目計時和執行的影響一樣。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
